Who
G. Bradley Cole
Director
Company insider
Files Form 4 as: Director, Kiniksa Pharmaceuticals International; Director, Castle Biosciences; General Manager - Diagnostics, Exact Sciences; CFO, Genomic Health.
In numbers
- Trades disclosed
- 546
- Buys
- 0
- Sells
- 115
- Bought
- $0
- Sold
- $34.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 30 Nov 2006
- Last trade
- 29 Jul 2026
- Last filed
- 31 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 31 Jul 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $299K3,673 at $81.43 | filing |
| 29 Jul 2026filed 31 Jul 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code G | —4,500 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $299K3,673 at $81.43 | filing |
| 29 Jul 2026filed 31 Jul 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code G | —4,500 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,799 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —12,158 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —2,026 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —12,158 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —2,026 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,799 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,799 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,799 | filing |
| 28 May 2026filed 1 Jun 2026 | CSTL Castle Biosciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,766 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | CSTL Castle Biosciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,766 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | CSTL Castle BiosciencesDiagnostics & Labs | SEC FORM 4 Code M | —13,667 | filing |
| 22 May 2026filed 27 May 2026 | CSTL Castle Biosciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —13,667 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | CSTL Castle Biosciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —13,667 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | CSTL Castle BiosciencesDiagnostics & Labs | SEC FORM 4 Code M | —13,667 | filing |
| 5 Mar 2026filed 9 Mar 2026 | CSTL Castle BiosciencesDiagnostics & Labs | SEC FORM 4 Code M | $16K4,748 at $3.38 | filing |
| 5 Mar 2026filed 9 Mar 2026 | CSTL Castle BiosciencesDiagnostics & Labs | SEC FORM 4 Sold | $135K4,748 at $28.44 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026Head to Head Analysis: Castle Biosciences (NASDAQ:CSTL) vs. Alignment Healthcare (NASDAQ:ALHC)CSTL · themarketsdaily.com · 15 Oct 2026Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of StockCSTL · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name G. Bradley Cole; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.